The Low-Hanging Fruit That Can Transform Healthcare Today
Kamal Anand, chief product officer of TeleVox and Mosaicx, part of West Technology Group.
In conversations across the healthcare industry, I see many healthcare leaders rightly focused on AI's long-term potential. But in doing so, they may overlook high-impact automation and digital engagement tools that can improve efficiency, reduce administrative burden and enhance patient experience and outcomes right now.
I believe in the power of automation and AI as augmentation tools. The most effective technologies currently in healthcare aren't designed to take over for humans; they're built to support them. They help care teams focus on what they do best while offloading the repetitive, routine and administrative work that weighs them down.
As a pragmatic product leader, I've seen firsthand that incremental improvements, particularly those powered by responsible AI and automation, can drive real, measurable impact. These smaller wins build confidence, prove ROI and pave the way for more transformative change down the road.
By reframing digital transformation as a process of enhancement rather than disruption, healthcare leaders can unlock value sooner and with less risk. And they don't need to wait for external technology partners or major capital investment to do it. The opportunity lies in optimizing underused capabilities and aligning existing systems around immediate pain points.
Transformation doesn't always mean disruption; it often means prioritization. While disruption focuses on replacing existing processes, true transformation enhances what already works. Many healthcare organizations are stalled by complexity, under-resourced teams or the misconception that meaningful change requires a wholesale overhaul. The result is digital paralysis—a wait-and-see posture that slows progress and sidelines practical improvements.
Leaders often feel pressured to make one big bet on AI or commit to large-scale electronic health record (EHR) upgrades, rather than sequencing more minor improvements that can demonstrate value quickly. However, incremental progress compounds. One study suggests that even a targeted workflow fix—automating a common task or reducing administrative rework—can deliver immediate returns and help teams build the momentum and trust needed to take on more ambitious projects.
There's also a misperception that if a solution isn't revolutionary, it's not worth the investment. But in healthcare, efficiency and access are deeply intertwined. In many cases, existing platforms already contain the capabilities needed to drive meaningful change, provided they're activated and aligned effectively.
Here are three areas healthcare organizations can win by adopting a "start small, scale smart" strategy, without tearing down and replacing existing systems.
Giving patients the ability to manage their care experience—like scheduling, prescription refills or updating forms—can ease administrative burdens and improve satisfaction. However, many health systems still require patients to use a single channel, such as a web portal, which limits adoption. A better approach is to meet patients where they are by offering self-service across channels they already use, including voice, text and online.
Starting small means identifying one high-volume task and then piloting automation with clear feedback loops. Use existing tools where possible and ensure staff workflows evolve alongside tech so that value isn't lost to confusion or duplication.
Referrals to specialists often involve manual outreach, missed calls and follow-up delays. For large systems, only a minority of referrals, as low as 34.8%, turn into appointments. That's lost revenue—and worse, delayed care.
One way to begin automating this flow is by building logic into your existing customer relationship management (CRM) system that triggers outreach once a referral is made. Let patients schedule through secure text, voice or online systems, and use reminders to reduce no-shows. Even partial automation can reduce leakage and free up scheduling staff. The key is to avoid changing everything at once. Focus on one specialty or location and scale from there.
Conversational AI tools have evolved far beyond basic chatbots. Today's AI-powered messaging systems can do more than help answer questions—they can provide educational resources and help patients navigate their care journeys. These systems scale communication efforts while preserving the human touch. For example, a conversational AI system might guide a patient through pre-visit instructions, post-discharge care or insurance questions, only escalating to a live agent when needed.
The study mentioned above indicates that AI-powered chatbots help reduce healthcare providers' workloads, allowing them to concentrate on more complicated cases that require their expertise. These tools minimize call center strain, improve response times and keep patients engaged throughout the care continuum by handling routine inquiries and providing around-the-clock support.
Organizations don't need to build from scratch to get started. Many can pilot AI-powered messaging by extending their current patient communication platforms or integrating with existing CRM systems. A small-scale rollout, such as AI for pre-visit preparation or post-discharge follow-up, can help teams test effectiveness, gather feedback and gradually expand based on need and performance.
Generative and agentic AI may be stealing the spotlight, but it's not the only form of intelligent technology delivering value in healthcare today. Leaders don't need to start with the most advanced capabilities to move the needle. Beginning with smaller, manageable steps sets the stage for faster adoption, clearer ROI and more substantial team alignment.
Getting started doesn't require major system upgrades. Many teams already have the infrastructure they need to begin automating routine workflows, whether it's appointment reminders, referral scheduling or billing notifications. The key is to take a realistic inventory of current platforms, identify friction points and apply automation where it can quickly relieve pressure.
Internal alignment matters just as much as the tech stack. Teams should be looped in early, with clear expectations around what automation will do and how it fits into their day-to-day responsibilities. Focus on projects that improve staff workflows, not just patient-facing touchpoints. Small efficiency wins—like reducing phone traffic or eliminating redundant data entry—can deliver measurable time savings and morale boosts.
Ultimately, digital transformation doesn't have to feel disruptive. With the proper framing, small-scale automation projects become a proving ground for larger innovation. They help teams build confidence, develop governance practices and scale what works.
Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
TechCrunch
12 minutes ago
- TechCrunch
Deezer starts labeling AI-generated music to tackle streaming fraud
Deezer announced on Friday that it will start labeling albums that include AI-generated tracks as part of its efforts to combat streaming fraud. The company reports that about 18% of the music uploaded each day — more than 20,000 tracks — is now fully AI-generated. Although most of these tracks don't go viral, Deezer says around 70% of their streams are fake and that they are designed to earn royalties fraudulently. To combat this, AI-generated tracks on Deezer are now clearly tagged. These tracks also won't appear in editorial playlists or algorithm-based recommendations, and fraudulent streams are being filtered out of royalty payments. The company says the new labels will be a game changer in helping listeners determine the difference between human-created music and AI content. Image Credits:Deezer Deezer notes that for now, AI-only songs make up just 0.5% of all streams on its platform, but that the trend is growing fast. 'We've detected a significant uptick in delivery of AI-generated music only in the past few months and we see no sign of it slowing down. It's an industry-wide issue, and we are committed to leading the way in increasing transparency by helping music fans identify which albums include AI music,' said Deezer CEO Alexis Lanternier in a press release. 'AI is not inherently good or bad, but we believe a responsible and transparent approach is key to building trust with our users and the music industry,' he continued. 'We are also clear in our commitment to safeguarding the rights of artists and songwriters at a time where copyright law is being put into question in favor of training AI models.' Techcrunch event Save $200+ on your TechCrunch All Stage pass Build smarter. Scale faster. Connect deeper. Join visionaries from Precursor Ventures, NEA, Index Ventures, Underscore VC, and beyond for a day packed with strategies, workshops, and meaningful connections. Save $200+ on your TechCrunch All Stage pass Build smarter. Scale faster. Connect deeper. Join visionaries from Precursor Ventures, NEA, Index Ventures, Underscore VC, and beyond for a day packed with strategies, workshops, and meaningful connections. Boston, MA | REGISTER NOW The move comes as Universal Music Group, Warner Music Group, and Sony Music Entertainment are reportedly in talks to license their work to AI startups Udio and Suno. The startups are being sued by the record companies for copyright infringement, and any deal would help to settle lawsuits between them, Bloomberg reported earlier this month.
Medscape
13 minutes ago
- Medscape
Key Abstracts in Early-Stage NSCLC From ASCO 2025
Dr Jonathan Goldman of the University of California, Los Angeles, highlights key abstracts in early-stage NSCLC from ASCO 2025. Dr Goldman begins with updated results from CheckMate 816, comparing neoadjuvant chemotherapy (chemo) vs chemo + nivolumab. Median overall survival (OS) in the nivolumab arm remains unreached vs 73.7 months with chemo alone. Event-free survival (EFS) is durable at 59.6 vs 21.1 months, as evidenced by 5-year EFS of 49% in the combination arm. Next, he reviews the NeoADAURA trial evaluating neoadjuvant osimertinib ± chemo in resectable EGFR-mutated stage II-IIIB NSCLC. Major pathologic response was higher in osimertinib-containing arms (26% and 25%) vs 2% in the chemo arm, although long-term outcomes remain pending. Dr Goldman also discusses the SWOG/NRG S1914 trial of perioperative stereotactic body radiotherapy ± atezolizumab, which did not show improvements in OS or progression-free survival (PFS). He then highlights a prospective, low-dose CT screening study of the Mississippi Delta cohort, which showed a 4.7% lung cancer detection rate overall and 4.5% in patients with incidental pulmonary nodules — underscoring the utility of low-dose CT as a modality in early detection. In closing, he reports on two studies in small cell lung cancer. The IMforte study showed that lurbinectedin + atezolizumab in 1L maintenance improved PFS (HR, 0.54). In the DeLLphi-304 study, second-line tarlatamab improved OS compared to chemo (HR, 0.6), which is a potentially practice-changing update.
Yahoo
13 minutes ago
- Yahoo
Could the "Next Nvidia Stock" Actually Be... Nvidia Stock?
There seems at least a solid probability that Nvidia stock still has not just good or even great but amazing growth potential left. Year-over-year earnings growth solidly in the double-digit percentages and a reasonable stock valuation should be all that's needed to keep Nvidia investors very happy. 10 stocks we like better than Nvidia › Many articles have been written over the last year or so about "the next Nvidia (NASDAQ: NVDA) stock," which refers to a stock that has the potential to post incredibly strong gains over at least the medium term, just like the artificial intelligence (AI) chip leader has done. With the risk of sounding like I've lost my mind, I think there's a good case to be made that "the next Nvidia stock" could actually be Nvidia stock. In other words, there seems at least a solid probability that Nvidia stock still has not just good or even great but amazing growth potential left. Think of it as "Nvidia the superstar stock 2.0." I say "at the risk of sounding like I've lost my mind" because I understand the law of large numbers strongly works against my thesis. This "law" basically means that the larger a company becomes, the more difficult it becomes to continue to grow revenue and earnings at a strong pace on a year-over-year percentage basis. And year-over-year earnings (and cash flow) growth is what largely powers stock prices higher. Nvidia is massive. It has a market cap of $3.55 trillion, as of June 18, making it the world's second most valuable publicly traded company, trailing Microsoft by just a sliver. Moreover, Nvidia management expects the company to generate revenue of $45 billion in its fiscal second quarter, which equates to an annual revenue run rate of $180 billion. To be clear -- I think it's highly unlikely that Nvidia will ever again be able to pump out a long consecutive string of year-over-year quarterly earnings growth in the very high double-digit to triple-digit percentages. But I don't think it has to do that in order to deliver stellar returns to investors for some time. Year-over-year earnings growth solidly in the double-digits plus a reasonable stock valuation should be all that's needed to keep investors very happy. What makes me have confidence in the "reasonable valuation" bit? Currently, Nvidia stock's valuation is reasonable by just about every measure, but that has not always been true. (For reference, it's trading at 25.4 times Wall Street's projected forward earnings per share, or EPS, as of June 18. That's an attractive valuation for a company that analysts expect will grow EPS at an average annual rate of 30% over the next five years.) The main reason I think the valuation will likely remain relatively reasonable (at least much of the time) for a while circles back to that law of large numbers. Wall Street analysts and many investors are well aware of this phenomenon, and I think most folks in both those groups will tend to continue to significantly underestimate Nvidia's future earnings growth potential due to thoughts like these: An investor and analyst thought: It's so massive, there's no way it can keep growing earnings much. An investor thought: After its massive run-up, I've missed my chance to buy Nvidia stock. (How many of us thought that about, say, Amazon many years ago, only to be proven wrong?) Consistent beliefs like these will help keep Nvidia stock's valuation reasonable in part because Wall Street analysts are going to tend to be too conservative in their estimates, in my view. Moreover, some investors will probably feel that Wall Street is being too liberal in their estimates because they themselves feel cautious given Nvidia's humongous size. Yes, this caution among many investors would likely slow down Nvidia stock's rise, but that's better than the stock frequently shooting up to unsustainable levels, only to plunge back down to Earth, in my opinion. This topic could be several articles, so here's just a brief list. 1. The company's now-annual cadence of launching new graphics processing unit (GPU) architectures for its products for its AI-accelerated data center, gaming, and other market platforms. Blackwell is its current architecture. 2. The approach of the widespread legalization of autonomous vehicles. Nvidia's GPUs will be the "brains" inside many of these vehicles. 3. The approach of the era of humanoid robots. Nvidia's GPUs will be the "brains" inside many of these robots. 4. The company will stay ahead of the innovation pack by entering emerging new technologies via organic growth and acquisitions. An example here is quantum computing, in which I think Nvidia will be increasingly involved. Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Beth McKenna has positions in Nvidia. The Motley Fool has positions in and recommends Amazon, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Could the "Next Nvidia Stock" Actually Be... Nvidia Stock? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
